Skip to main content
Springer Nature Link
Log in

The Role of Creatine in the Management of Amyotrophic Lateral Sclerosis and Other Neurodegenerative Disorders

  • Leading Article
  • Published:
Save article
View saved research
CNS Drugs Aims and scope Submit manuscript

Abstract

Creatine is consumed in the diet and endogenously synthesised in the body. Over the past decade, the ergogenic benefits of synthetic creatine monohydrate have made it a popular dietary supplement, particularly among athletes. The anabolic properties of creatine also offer hope for the treatment of diseases characterised by weakness and muscle atrophy. Moreover, because of its cellular mechanisms of action, creatine offers potential benefits for diseases involving mitochondrial dysfunction. Recent data also support the hypothesis that creatine may have a neuroprotective effect.

Amyotrophic lateral sclerosis (ALS) is characterised by progressive degeneration of motor neurons, resulting in weakening and atrophy of skeletal muscles. In patients with this condition, creatine offers potential benefits in terms of facilitating residual muscle contractility as well as improving neuronal function. It may also help stabilise mitochondrial dysfunction, which plays a key role in the pathogenesis of ALS. Indeed, the likely multifactorial aetiology of ALS means the combined pharmacodynamic properties of creatine offer promise for the treatment of this condition.

Evidence from available animal models of ALS supports the utility of treatment with creatine in this setting. Limited data available in other neuromuscular and neurodegenerative diseases further support the potential benefit of creatine monohydrate in ALS. However, few randomised, controlled trials have been conducted. To date, two clinical trials of creatine monohydrate in ALS have been completed without demonstration of significant improvements in overall survival or a composite measure of muscle strength. These trials have also posed unanswered questions about the optimal dosage of creatine and its beneficial effects on muscle fatigue, a measure distinct from muscle strength. A large, multicentre, clinical trial is currently underway to further investigate the efficacy of creatine monohydrate in ALS and address these unresolved issues. Evidence to date shows that creatine supplementation has a good safety profile and is well tolerated by ALS patients.

The purpose of this article is to provide a short, balanced review of the literature concerning creatine monohydrate in the treatment of ALS and related neurodegenerative diseases. The pharmacokinetics and rationale for the use of creatine are described along with available evidence from animal models and clinical trials for ALS and related neurodegenerative or neuromuscular diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+
from $39.99 /Month
  • Starting from 10 chapters or articles per month
  • Access and download chapters and articles from more than 300k books and 2,500 journals
  • Cancel anytime
View plans

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
The alternative text for this image may have been generated using AI.
Table II
The alternative text for this image may have been generated using AI.

Similar content being viewed by others

Explore related subjects

Discover the latest articles, books and news in related subjects, suggested using machine learning.

References

  1. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344(22): 1688–700

    PubMed  CAS  Google Scholar 

  2. Cluskey S, Ramsden DB. Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. Mol Pathol 2001; 54(6): 386–92

    PubMed  CAS  Google Scholar 

  3. Rosen DR. Mutations in Cu/Zn superoxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59–62

    PubMed  CAS  Google Scholar 

  4. Ferrante RJ, Shinobu LA, Schulz JB, et al. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 1997; 42(3): 326–34

    PubMed  CAS  Google Scholar 

  5. Andersen P, Morita M, Brown R. Genetics of amyotrophic lateral sclerosis: an overview. In: Brown R, Meininger V, Swash M, editors. Amyotrophic lateral sclerosis. London: Martin-Dunitz, 2000

    Google Scholar 

  6. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992; 59(5): 1609–23

    PubMed  CAS  Google Scholar 

  7. Halliwell B. Oxygen radicals as key mediators in neurological disease: fact or fiction? Ann Neurol 1992; 32 Suppl.: S10–15

    PubMed  CAS  Google Scholar 

  8. Beckman JS, Estevez AG, Crow JP, et al. Superoxide dismutase and the death of motoneurons in ALS. Trends Neurosci 2001; 24(11 Suppl.): S15–20

    PubMed  CAS  Google Scholar 

  9. Brown RH. Superoxide dismutase and familial amyotrophic lateral sclerosis: new insights into mechanisms and treatments. Ann Neurol 1996; 39(2): 145–6

    PubMed  Google Scholar 

  10. Menzies FM, Cookson MR, Taylor RW, et al. Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain 2002; 125 (Pt 7): 1522–33

    PubMed  Google Scholar 

  11. Menzies FM, Ince PG, Shaw PJ. Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem Int 2002; 40(6): 543–51

    PubMed  CAS  Google Scholar 

  12. Jung C, Higgins CM, Xu Z. Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis. J Neurochem 2002; 83(3): 535–45

    PubMed  CAS  Google Scholar 

  13. Kaal EC, Vlug AS, Versleijen MW, et al. Chronic mitochondrial inhibition induces selective motoneuron death in vitro: a new model for amyotrophic lateral sclerosis. J Neurochem 2000; 74(3): 1158–65

    PubMed  CAS  Google Scholar 

  14. Bowling AC, Schulz JB, Brown RH, et al. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1993; 61(6): 2322–5

    PubMed  CAS  Google Scholar 

  15. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992; 31(2): 119–30

    PubMed  CAS  Google Scholar 

  16. Fosslien E. Mitochondrial medicine: molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci 2001; 31(1): 25–67

    PubMed  CAS  Google Scholar 

  17. Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999; 58(5): 459–71

    PubMed  CAS  Google Scholar 

  18. Rothstein JD, Kuncl R, Chaudhry V, et al. Excitatory amino acids in amyotrophic lateral sclerosis: an update. Ann Neurol 1991; 30(2): 224–5

    PubMed  CAS  Google Scholar 

  19. Rothstein JD. Therapeutic horizons for amyotrophic lateral sclerosis. Curr Opin Neurobiol 1996; 6(5): 679–87

    PubMed  CAS  Google Scholar 

  20. Kruman II, Pedersen WA, Springer JE, et al. ALS-linked Cu/ Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp Neurol 1999; 160(1): 28–39

    PubMed  CAS  Google Scholar 

  21. Carri MT, Ferri A, Battistoni A, et al. Expression of a Cu,Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis induces mitochondrial alteration and increase of cytosolic Ca2+ concentration in transfected neuroblastoma SH-SY5Y cells. FEBS Lett 1997; 414(2): 365–8

    PubMed  CAS  Google Scholar 

  22. Canton T, Pratt J, Stutzmann JM, et al. Glutamate uptake is decreased tardively in the spinal cord of FALS mice. Neuroreport 1998; 9(5): 775–8

    PubMed  CAS  Google Scholar 

  23. Trotti D, Rolfs A, Danbolt NC, et al. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter [published erratum appears in Nat Neurosci 1999 Sep; 2(9): 848]. Nat Neurosci 1999; 2(5): 427–33

    PubMed  CAS  Google Scholar 

  24. Howland DS, Liu J, She Y, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A 2002; 99(3): 1604–9

    PubMed  CAS  Google Scholar 

  25. Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 2000; 130(4S Suppl.): 1007–1015S

    Google Scholar 

  26. Schulz JB, Lindenau J, Seyfried J, et al. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 2000; 267(16): 4904–11

    PubMed  CAS  Google Scholar 

  27. Campiani G, Fattorusso C, De Angelis M, et al. Neuronal high-affinity sodium-dependent glutamate transporters (EAATs): targets for the development of novel therapeutics against neurodegenerative diseases. Curr Pharm Des 2003; 9(8): 599–625

    PubMed  CAS  Google Scholar 

  28. Pearson AM, Young RB. Diseases and disorders of muscle. Adv Food Nutr Res 1993; 37: 339–423

    PubMed  CAS  Google Scholar 

  29. Persky AM, Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev 2001; 53(2): 161–76

    PubMed  CAS  Google Scholar 

  30. Jacobs I. Dietary creatine monohydrate supplementation. Can J Appl Physiol 1999; 24(6): 503–14

    PubMed  CAS  Google Scholar 

  31. Greenhaff PL. Creatine and its application as an ergogenic aid. Int J Sport Nutr 1995; 5 Suppl.: S100–110

    PubMed  Google Scholar 

  32. Greenhaff PL, Bodin K, Soderlund K, et al. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. Am J Physiol 1994; 266 (5 Pt 1): E725–730

    PubMed  CAS  Google Scholar 

  33. Bogdanis GC, Nevill ME, Boobis LH, et al. Contribution of phosphocreatine and aerobic metabolism to energy supply during repeated sprint exercise. J Appl Physiol 1996; 80(3): 876–84

    PubMed  CAS  Google Scholar 

  34. Benzi G, Ceci A. Creatine as nutritional supplementation and medicinal product. J Sports Med Phys Fitness 2001; 41(1): 1–10

    PubMed  CAS  Google Scholar 

  35. Guerrero-Ontiveros ML, Wallimann T. Creatine supplementation in health and disease: effects of chronic creatine ingestion in vivo: down-regulation of the expression of creatine transporter isoforms in skeletal muscle. Mol Cell Biochem 1998; 184(1–2): 427–37

    PubMed  CAS  Google Scholar 

  36. Febbraio MA, Flanagan TR, Snow RJ, et al. Effect of creatine supplementation on intramuscular TCr, metabolism and performance during intermittent, supramaximal exercise in humans. Acta Physiol Scand 1995; 155(4): 387–95

    PubMed  CAS  Google Scholar 

  37. Hultman E, Soderlund K, Timmons JA, et al. Muscle creatine loading in men. J Appl Physiol 1996; 81(1): 232–7

    PubMed  CAS  Google Scholar 

  38. Tarnopolsky MA, MacLennan DP. Creatine monohydrate supplementation enhances high-intensity exercise performance in males and females. Int J Sport Nutr Exerc Metab 2000; 10(4): 452–63

    PubMed  CAS  Google Scholar 

  39. Harris RC, Soderlund K, Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin Sci 1992; 83(3): 367–74

    PubMed  CAS  Google Scholar 

  40. Casey A, Greenhaff PL. Does dietary creatine supplementation play a role in skeletal muscle metabolism and performance? Am J Clin Nutr 2000; 72(2 Suppl.): 607–617S

    Google Scholar 

  41. Tarnopolsky MA. Potential benefits of creatine monohydrate supplementation in the elderly. Curr Opin Clin Nutr Metab Care 2000; 3(6): 497–502

    PubMed  CAS  Google Scholar 

  42. Terjung RL, Clarkson P, Eichner ER, et al. American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation. Med Sci Sports Exerc 2000; 32(3): 706–17

    CAS  Google Scholar 

  43. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997; 20(12): 1502–9

    PubMed  CAS  Google Scholar 

  44. Pulido SM, Passaquin AC, Leijendekker WJ, et al. Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells. FEBS Lett 1998; 439(3): 357–62

    PubMed  CAS  Google Scholar 

  45. Felber S, Skladal D, Wyss M, et al. Oral creatine supplementation in Duchenne muscular dystrophy: a clinical and 31P magnetic resonance spectroscopy study. Neurol Res 2000; 22(2): 145–50

    PubMed  CAS  Google Scholar 

  46. Harris RC, Nevill M, Harris DB, et al. Absorption of creatine supplied as a drink, in meat or in solid form. J Sports Sci 2002; 20(2): 147–51

    PubMed  Google Scholar 

  47. Haugland RB, Chang DT. Insulin effect on creatine transport in skelatal muscle (38464). Proc Soc Exp Biol Med 1975; 148(1): 1–4

    PubMed  CAS  Google Scholar 

  48. Koszalka TR, Andrew CL, Brent RL. Effect of insulin on the uptake of creatine-1-14 C by skeletal muscle in normal and x-irradiated rats. Proc Soc Exp Biol Med 1972; 139(4): 1265–71

    PubMed  CAS  Google Scholar 

  49. Steenge GR, Lambourne J, Casey A, et al. Stimulatory effect of insulin on creatine accumulation in human skeletal muscle. Am J Physiol 1998; 275 (6 Pt 1): E974–979

    PubMed  CAS  Google Scholar 

  50. Steenge GR, Simpson EJ, Greenhaff PL. Protein- and carbohydrate-induced augmentation of whole body creatine retention in humans. J Appl Physiol 2000; 89(3): 1165–71

    PubMed  CAS  Google Scholar 

  51. Green AL, Hultman E, Macdonald IA, et al. Carbohydrate ingestion augments skeletal muscle creatine accumulation during creatine supplementation in humans. Am J Physiol 1996; 271 (5 Pt 1): E821–826

    PubMed  CAS  Google Scholar 

  52. Vandenberghe K, Gillis N, Van Leemputte M, et al. Caffeine counteracts the ergogenic action of muscle creatine loading. J Appl Physiol 1996; 80(2): 452–7

    PubMed  CAS  Google Scholar 

  53. Doherty M, Smith PM, Davison RC, et al. Caffeine is ergogenic after supplementation of oral creatine monohydrate. Med Sci Sports Exerc 2002; 34(11): 1785–92

    PubMed  CAS  Google Scholar 

  54. Kreider RB, Ferreira M, Wilson M, et al. Effects of creatine supplementation on body composition, strength, and sprint performance. Med Sci Sports Exerc 1998; 30(1): 73–82

    PubMed  CAS  Google Scholar 

  55. Vandenberghe K, Goris M, Van Hecke P, et al. Long-term creatine intake is beneficial to muscle performance during resistance training. J Appl Physiol 1997; 83(6): 2055–63

    PubMed  CAS  Google Scholar 

  56. Birch R, Noble D, Greenhaff PL. The influence of dietary creatine supplementation on performance during repeated bouts of maximal isokinetic cycling in man. Eur J Appl Physiol Occup Physiol 1994; 69(3): 268–76

    PubMed  CAS  Google Scholar 

  57. Bosco C, Tihanyi J, Pucspk J, et al. Effect of oral creatine supplementation on jumping and running performance. Int J Sports Med 1997; 18(5): 369–72

    PubMed  CAS  Google Scholar 

  58. Dawson B, Cutler M, Moody A, et al. Effects of oral creatine loading on single and repeated maximal short sprints. Aust J Sci Med Sport 1995; 27(3): 56–61

    PubMed  CAS  Google Scholar 

  59. Engelhardt M, Neumann G, Berbalk A, et al. Creatine supplementation in endurance sports. Med Sci Sports Exerc 1998; 30(7): 1123–9

    PubMed  CAS  Google Scholar 

  60. Grindstaff PD, Kreider R, Bishop R, et al. Effects of creatine supplementation on repetitive sprint performance and body composition in competitive swimmers. Int J Sport Nutr 1997; 7(4): 330–46

    PubMed  CAS  Google Scholar 

  61. Maganaris CN, Maughan RJ. Creatine supplementation enhances maximum voluntary isometric force and endurance capacity in resistance trained men. Acta Physiol Scand 1998; 163(3): 279–87

    PubMed  CAS  Google Scholar 

  62. McNaughton LR, Dalton B, Tarr J. The effects of creatine supplementation on high-intensity exercise performance in elite performers. Eur J Appl Physiol Occup Physiol 1998; 78(3): 236–40

    PubMed  CAS  Google Scholar 

  63. Prevost MC, Nelson AG, Morris GS. Creatine supplementation enhances intermittent work performance. Res Q Exerc Sport 1997; 68(3): 233–40

    PubMed  CAS  Google Scholar 

  64. Schneider DA, McDonough PJ, Fadel PJ, et al. Creatine supplementation and the total work performed during 15-s and 1-min bouts of maximal cycling. Aust J Sci Med Sport 1997; 29(3): 65–8

    PubMed  CAS  Google Scholar 

  65. Smith JC, Stephens DP, Hall EL, et al. Effect of oral creatine ingestion on parameters of the work rate-time relationship and time to exhaustion in high-intensity cycling. Eur J Appl Physiol Occup Physiol 1998; 77(4): 360–5

    PubMed  CAS  Google Scholar 

  66. Casey A, Constantin-Teodosiu D, Howell S, et al. Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. Am J Physiol 1996; 271 (1 Pt 1): E31–37

    PubMed  CAS  Google Scholar 

  67. Earnest CP, Snell PG, Rodriguez R, et al. The effect of creatine monohydrate ingestion on anaerobic power indices, muscular strength and body composition. Acta Physiol Scand 1995; 153(2): 207–9

    PubMed  Google Scholar 

  68. Juhn MS, Tarnopolsky M. Oral creatine supplementation and athletic performance: a critical review [published erratum appears in Clin J Sport Med 1999 Apr; 9 (2): 62]. Clin J Sport Med 1998; 8(4): 286–97

    PubMed  CAS  Google Scholar 

  69. Van Schuylenbergh R, Van Leemputte M, Hespel P. Effects of oral creatine-pyruvate supplementation in cycling performance. Int J Sports Med 2003; 24(2): 144–50

    PubMed  Google Scholar 

  70. Snow RJ, Turnbull J, da Silva S, et al. Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience 2003; 119(3): 661–7

    PubMed  CAS  Google Scholar 

  71. Odland LM, MacDougall JD, Tarnopolsky MA, et al. Effect of oral creatine supplementation on muscle [PCr] and short-term maximum power output. Med Sci Sports Exerc 1997; 29(2): 216–9

    PubMed  CAS  Google Scholar 

  72. Barnett C, Hinds M, Jenkins DG. Effects of oral creatine supplementation on multiple sprint cycle performance. Aust J Sci Med Sport 1996; 28(1): 35–9

    PubMed  CAS  Google Scholar 

  73. Preen D, Dawson B, Goodman C, et al. Pre-exercise oral creatine ingestion does not improve prolonged intermittent sprint exercise in humans. J Sports Med Phys Fitness 2002; 42(3): 320–9

    PubMed  CAS  Google Scholar 

  74. Lemon PW. Dietary creatine supplementation and exercise performance: why inconsistent results? Can J Appl Physiol 2002; 27(6): 663–81

    PubMed  CAS  Google Scholar 

  75. Wyss M, Wallimann T. Creatine metabolism and the consequences of creatine depletion in muscle. Mol Cell Biochem 1994; 133-134: 51–66

    Google Scholar 

  76. Brannon TA, Adams GR, Conniff CL, et al. Effects of creatine loading and training on running performance and biochemical properties of rat skeletal muscle. Med Sci Sports Exerc 1997; 29(4): 489–95

    PubMed  CAS  Google Scholar 

  77. Balsom PD, Harridge SD, Soderlund K, et al. Creatine supplementation per se does not enhance endurance exercise performance. Acta Physiol Scand 1993; 149(4): 521–3

    PubMed  CAS  Google Scholar 

  78. Bemben MG, Bemben DA, Loftiss DD, et al. Creatine supplementation during resistance training in college football athletes. Med Sci Sports Exerc 2001; 33(10): 1667–73

    PubMed  CAS  Google Scholar 

  79. Clarkson PM, Rawson ES. Nutritional supplements to increase muscle mass. Crit Rev Food Sci Nutr 1999; 39(4): 317–28

    PubMed  CAS  Google Scholar 

  80. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999; 5(3): 347–50

    PubMed  CAS  Google Scholar 

  81. Dolder M, Wendt S, Wallimann T. Mitochondrial creatine kinase in contact sites: interaction with porin and adenine nucleotide translocase, role in permeability transition and sensitivity to oxidative damage. Biol Signals Recept 2001; 10(1–2): 93–111

    PubMed  CAS  Google Scholar 

  82. WallimannT, Wyss M, Brdiczka D, et al. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the ‘phosphocreatine circuit’ for cellular energy homeostasis. Biochem J 1992; 281 (Pt 1): 21–40

    Google Scholar 

  83. Fontaine E, Bernardi P. Progress on the mitochondrial permeability transition pore: regulation by complex I and ubiquinone analogs. J Bioenerg Biomembr 1999; 31(4): 335–45

    PubMed  CAS  Google Scholar 

  84. Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 2001; 49(5): 561–74

    PubMed  CAS  Google Scholar 

  85. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington’s disease. J Neurosci 2000; 20(12): 4389–97

    PubMed  CAS  Google Scholar 

  86. Steeghs K, Benders A, Oerlemans F, et al. Altered Ca2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies. Cell 1997; 89(1): 93–103

    PubMed  CAS  Google Scholar 

  87. de Groof AJ, Fransen JA, Errington RJ, et al. The creatine kinase system is essential for optimal refill of the sarcoplasmic reticulum Ca2+ store in skeletal muscle. J Biol Chem 2002; 277(7): 5275–84

    PubMed  Google Scholar 

  88. Andreassen OA, Jenkins BG, Dedeoglu A, et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem 2001; 77(2): 383–90

    PubMed  CAS  Google Scholar 

  89. Xu CJ, Klunk WE, Kanfer JN, et al. Phosphocreatine-dependent glutamate uptake by synaptic vesicles: a comparison with atp-dependent glutamate uptake. J Biol Chem 1996; 271(23): 13435–40

    PubMed  CAS  Google Scholar 

  90. Brewer GJ, Wallimann TW. Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons. J Neurochem 2000; 74(5): 1968–78

    PubMed  CAS  Google Scholar 

  91. Lawler JM, Barnes WS, Wu G, et al. Direct antioxidant properties of creatine. Biochem Biophys Res Commun 2002; 290(1): 47–52

    PubMed  CAS  Google Scholar 

  92. Derave W, Van Den Bosch L, Lemmens G, et al. Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatment. Neurobiol Dis 2003 Aug; 13(3): 264–72

    PubMed  CAS  Google Scholar 

  93. Matthews RT, Yang L, Jenkins BG, et al. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington’s disease. J Neurosci 1998; 18(1): 156–63

    PubMed  CAS  Google Scholar 

  94. Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 2003; 53(2): 267–70

    PubMed  CAS  Google Scholar 

  95. Klivenyi P, Kiaei M, Gardian G, et al. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2004; 88(3): 576–82

    PubMed  CAS  Google Scholar 

  96. Shefner J, Cudkowicz M, Shchoenfeld D, et al. A clinical trial of creatine in patients with amyotrophic lateral sclerosis. Abstracts from the 14th International Symposium on ALS/MND. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4Suppl. 1: 28–9

    Google Scholar 

  97. Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53(4): 437–45

    PubMed  CAS  Google Scholar 

  98. Drory VE, Gross D. No effect of creatine on respiratory distress in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3(1): 43–6

    PubMed  CAS  Google Scholar 

  99. Mazzini L, Balzarini C, Colombo R, et al. Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. J Neurol Sci 2001; 191(1–2): 139–44

    PubMed  CAS  Google Scholar 

  100. Rosenfeld J, Jackson C, Smith J, et al. A pilot trial of ultrapure creatine in amyotrophic lateral sclerosis [abstract]. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2Suppl 2 (1466-0822): 20

    Google Scholar 

  101. Matthews RT, Ferrante RJ, Klivenyi P, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 1999; 157(1): 142–9

    PubMed  CAS  Google Scholar 

  102. Shear DA, Haik KL, Dunbar GL. Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats. Neuroreport 2000; 11(9): 1833–7

    PubMed  CAS  Google Scholar 

  103. Dedeoglu A, Kubilus JK, Yang L, et al. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington’s disease transgenic mice. J Neurochem 2003; 85(6): 1359–67

    PubMed  CAS  Google Scholar 

  104. Walter MC, Reilich P, Lochmuller H, et al. Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study. J Neurol 2002; 249(12): 1717–22

    PubMed  CAS  Google Scholar 

  105. Doherty TJ, Lougheed K, Markez J, et al. Creatine monohydrate does not increase strength in patients with hereditary neuropathy. Neurology 2001; 57(3): 559–60

    PubMed  CAS  Google Scholar 

  106. Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999; 52(4): 854–7

    PubMed  CAS  Google Scholar 

  107. Passaquin AC, Renard M, Kay L, et al. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul Disord 2002; 12(2): 174–82

    PubMed  Google Scholar 

  108. Walter MC, Lochmuller H, Reilich P, et al. Creatine monohydrate in muscular dystrophies: a double-blind, placebo-controlled clinical study. Neurology 2000; 54(9): 1848–50

    PubMed  CAS  Google Scholar 

  109. Louis M, Lebacq J, Poortmans JR, et al. Beneficial effects of creatine supplementation in dystrophic patients. Muscle Nerve 2003; 27(5): 604–10

    PubMed  CAS  Google Scholar 

  110. Juhn MS, Tarnopolsky M. Potential side effects of oral creatine supplementation: a critical review [published erratum appears in Clin J Sport Med 1999 Apr; 9 (2): 62]. Clin J Sport Med 1998; 8(4): 298–304

    PubMed  CAS  Google Scholar 

  111. Schilling BK, Stone MH, Utter A, et al. Creatine supplementation and health variables: a retrospective study. Med Sci Sports Exerc 2001; 33(2): 183–8

    PubMed  CAS  Google Scholar 

  112. Tarnopolsky MA, Parise G, Yardley NJ, et al. Creatine-dextrose and protein-dextrose induce similar strength gains during training. Med Sci Sports Exerc 2001; 33(12): 2044–52

    PubMed  CAS  Google Scholar 

  113. Ingwall JS, Morales MF, Stockdale FE. Creatine and the control of myosin synthesis in differentiating skeletal muscle. Proc Natl Acad Sci U S A 1972; 69(8): 2250–3

    PubMed  CAS  Google Scholar 

  114. Ingwall JS, Weiner CD, Morales MF, et al. Specificity of creatine in the control of muscle protein synthesis. J Cell Biol 1974; 62(1): 145–51

    PubMed  CAS  Google Scholar 

  115. Ingwall JS, Morales MF, Stockdale FE, et al. Creatine: a possible stimulus skeletal cardiac muscle hypertrophy. Recent Adv Stud Cardiac Struct Metab 1975; 8: 467–81

    PubMed  CAS  Google Scholar 

  116. Ingwall JS. Creatine and the control of muscle-specific protein synthesis in cardiac and skeletal muscle. Circ Res 1976; 38(5 Suppl. 1): I115–123

    Google Scholar 

  117. Parise G, Mihic S, MacLennan D, et al. Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis. J Appl Physiol 2001; 91(3): 1041–7

    PubMed  CAS  Google Scholar 

  118. Vierck JL, Icenoggle DL, Bucci L, et al. The effects of ergogenic compounds on myogenic satellite cells. Med Sci Sports Exerc 2003; 35(5): 769–76

    PubMed  CAS  Google Scholar 

  119. Dangott B, Schultz E, Mozdziak PE. Dietary creatine monohydrate supplementation increases satellite cell mitotic activity during compensatory hypertrophy. Int J Sports Med 2000; 21(1): 13–6

    PubMed  CAS  Google Scholar 

  120. Wyss M, Felber S, Skladal D, et al. The therapeutic potential of oral creatine supplementation in muscle disease. Med Hypotheses 1998; 51(4): 333–6

    PubMed  CAS  Google Scholar 

  121. Tarnopolsky M, Parise G, Fu MH, et al. Acute and moderateterm creatine monohydrate supplementation does not affect creatine transporter mRNA or protein content in either young or elderly humans. Mol Cell Biochem 2003; 244(1–2): 159–66

    PubMed  CAS  Google Scholar 

  122. Mihic S, MacDonald JR, McKenzie S, et al. Acute creatine loading increases fat-free mass, but does not affect blood pressure, plasma creatinine, or CK activity in men and women. Med Sci Sports Exerc 2000; 32(2): 291–6

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The Carolinas Neuromuscular/ALS Center is currently conducting a double-blind, placebo-controlled, multicentre study of the efficacy of creatine in patients with ALS. This study is funded by the National Institutes of Health (NIH) with The Avicena Group Inc. providing study medications and data management.

Author information

Authors and Affiliations

  1. Carolinas Neuromuscular/ALS Center, 1000 Blythe Boulevard, Charlotte, North Carolina, 28203, USA

    Amy Cameron Ellis & Jeffrey Rosenfeld

Authors
  1. Amy Cameron Ellis
    View author publications

    Search author on:PubMed Google Scholar

  2. Jeffrey Rosenfeld
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Amy Cameron Ellis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ellis, A.C., Rosenfeld, J. The Role of Creatine in the Management of Amyotrophic Lateral Sclerosis and Other Neurodegenerative Disorders. CNS Drugs 18, 967–980 (2004). https://doi.org/10.2165/00023210-200418140-00002

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.2165/00023210-200418140-00002

Keywords